董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jose Carlos Gutierrez Ramos | -- | Independent Director | 63 | 未披露 | 未持股 | 2025-09-08 |
| Kevin Lee | 男 | Director and Chief Executive Officer | 56 | 250.67万美元 | 未持股 | 2025-09-08 |
| Greg Winter | 男 | Independent Director | 73 | 13.58万美元 | 未持股 | 2025-09-08 |
| Janice Bourque | 女 | Independent Director | 68 | 20.64万美元 | 未持股 | 2025-09-08 |
| Charles Swanton | -- | Director | -- | 未披露 | 未持股 | 2025-09-08 |
| Felix J. Baker | -- | Chairman of the Board | -- | 未披露 | 未持股 | 2025-09-08 |
| Fabrice Andre | -- | Director | -- | 未披露 | 未持股 | 2025-09-08 |
| Alessandro Riva | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-08 |
| Stephen Sands | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-08 |
| Roger Danse | 男 | Director | -- | 未披露 | 未持股 | 2025-09-08 |
| Hervé Hoppenot | 男 | Director | -- | 未披露 | 未持股 | 2025-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin Lee | 男 | Director and Chief Executive Officer | 56 | 250.67万美元 | 未持股 | 2025-09-08 |
| Michael Skynner | 男 | Chief Technology Officer | 56 | 115.47万美元 | 未持股 | 2025-09-08 |
| Travis Thompson | -- | Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-09-08 |
| Eric Westin | -- | Chief Medical Officer | -- | 未披露 | 未持股 | 2025-09-08 |
| Alethia Young | -- | Chief Financial Officer | -- | 未披露 | 未持股 | 2025-09-08 |
| Alistair Milnes | -- | Chief Operating Officer | -- | 未披露 | 未持股 | 2025-09-08 |
| Michael Charles Ferguson Hannay | -- | Chief Product Officer and Chief Supply Chain Officer | -- | 未披露 | 未持股 | 2025-09-08 |
| Jim MacDonald Clink | -- | Senior Vice President and Head of Business Development | -- | 未披露 | 未持股 | 2025-09-08 |
董事简历
中英对照 | 中文 | 英文- Jose Carlos Gutierrez Ramos
-
Jose Carlos Gutierrez Ramos自2020年12月加入Danaher 以来，一直担任高级副总裁兼首席科学官。在加入Danaher 之前，Gutierrez-Ramos博士于2020年1月至2020年12月担任生物制药公司AbbVie，Inc.的药物发现副总裁；于2018年8月至2020年1月担任生物技术公司Repertoire Immune Medicines的总裁兼首席执行官；于2015年8月至2018年8月担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。
Jose Carlos Gutierrez Ramos,has served as Senior Vice President – Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President – Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020. - Jose Carlos Gutierrez Ramos自2020年12月加入Danaher 以来，一直担任高级副总裁兼首席科学官。在加入Danaher 之前，Gutierrez-Ramos博士于2020年1月至2020年12月担任生物制药公司AbbVie，Inc.的药物发现副总裁；于2018年8月至2020年1月担任生物技术公司Repertoire Immune Medicines的总裁兼首席执行官；于2015年8月至2018年8月担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。
- Jose Carlos Gutierrez Ramos,has served as Senior Vice President – Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President – Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020.
- Kevin Lee
-
Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
Kevin Lee,has served as Chief Executive Officer and a member of Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020. - Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
- Kevin Lee,has served as Chief Executive Officer and a member of Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020.
- Greg Winter
-
Greg Winteris FRS是我们的联合创始人，自我们成立以来一直担任我们的董事会成员。Greg爵士从1981年到2012年担任英国剑桥医学研究委员会分子生物学实验室（Medical Research Council Laboratory of Molecular Biology LMB）的工作人员，担任副主任和代理主任。他目前是剑桥大学三一学院的院士，此前曾于2012年10月至2019年6月担任剑桥大学三一学院硕士。Greg爵士还担任生物技术公司的顾问。格雷格爵士是英国皇家学会会员，于2004年因对科学的贡献而被封为爵士。2018年，格雷格爵士（Sir Greg）因开发噬菌体显示器（英语:Phage display）用于抗体和肽的定向进化以生产新药而获得诺贝尔化学奖。2016年至2018年，他一直担任BioSceptre International Limited的代理主席。Greg爵士曾是Cambridge Antibody Technology和Domantis的创始人和非执行董事。
Greg Winter is Co-Founder and has served on of Board since inception. Sir Greg was a member of staff of the Medical Research Council Laboratory of Molecular Biology LMB in Cambridge, U.K. from 1981 to 2012 serving as both Deputy and Acting Director. He is currently a Fellow of Trinity College, Cambridge and was previously a Master of Trinity College, Cambridge from October 2012 to June 2019. Sir Greg also serves as a consultant to biotechnology companies. Sir Greg is a Fellow of the Royal Society and was knighted in 2004 for services to science. In 2018 Sir Greg was awarded a Nobel Prize in Chemistry for his work in developing phage display for the directed evolution of antibodies and peptides to produce new medicines. He has been the Acting Chairman of Biosceptre International Limited from 2016 to 2018. Sir Greg was a founder and non-Executive Director of Cambridge Antibody Technology and Domantis. - Greg Winteris FRS是我们的联合创始人，自我们成立以来一直担任我们的董事会成员。Greg爵士从1981年到2012年担任英国剑桥医学研究委员会分子生物学实验室（Medical Research Council Laboratory of Molecular Biology LMB）的工作人员，担任副主任和代理主任。他目前是剑桥大学三一学院的院士，此前曾于2012年10月至2019年6月担任剑桥大学三一学院硕士。Greg爵士还担任生物技术公司的顾问。格雷格爵士是英国皇家学会会员，于2004年因对科学的贡献而被封为爵士。2018年，格雷格爵士（Sir Greg）因开发噬菌体显示器（英语:Phage display）用于抗体和肽的定向进化以生产新药而获得诺贝尔化学奖。2016年至2018年，他一直担任BioSceptre International Limited的代理主席。Greg爵士曾是Cambridge Antibody Technology和Domantis的创始人和非执行董事。
- Greg Winter is Co-Founder and has served on of Board since inception. Sir Greg was a member of staff of the Medical Research Council Laboratory of Molecular Biology LMB in Cambridge, U.K. from 1981 to 2012 serving as both Deputy and Acting Director. He is currently a Fellow of Trinity College, Cambridge and was previously a Master of Trinity College, Cambridge from October 2012 to June 2019. Sir Greg also serves as a consultant to biotechnology companies. Sir Greg is a Fellow of the Royal Society and was knighted in 2004 for services to science. In 2018 Sir Greg was awarded a Nobel Prize in Chemistry for his work in developing phage display for the directed evolution of antibodies and peptides to produce new medicines. He has been the Acting Chairman of Biosceptre International Limited from 2016 to 2018. Sir Greg was a founder and non-Executive Director of Cambridge Antibody Technology and Domantis.
- Janice Bourque
-
Janice Bourque自2019年7月起担任董事会成员。Bourque女士是Hercules Capital生命科学集团的常务董事，拥有超过25年的生命科学经验，专注于新兴成长阶段公司。在此之前，Bourque女士曾为Commons Capital提供咨询，担任Comerica Bank的高级副总裁和生命科学集团负责人，并担任马萨诸塞州生物技术委员会主席兼首席执行官。Bourque女士目前在Poxel，SA和The Village Bank的董事会任职。Bourque女士还担任麻省理工学院科赫综合癌症研究所（MIT Koch Institute for Integrative Cancer Research）的董事会成员。她持有the University of New Hampshire的兽医科学B.S.和财务和会计工商管理硕士学位。
Janice Bourque has served as a member of Board since July 2019. Ms. Bourque is a Managing Director in Hercules Capital's life sciences group and has more than 25 years of life science experience and a focus on emerging growth stage companies. Previously, Ms. Bourque has consulted for Commons Capital, served as Senior Vice President and Group Head Life Sciences at Comerica Bank and was President and Chief Executive Officer of the Massachusetts Biotechnology Council. Ms. Bourque currently serves on the board of directors of Poxel, SA and the Village Bank. Ms. Bourque has also served on the board of directors of the MIT Koch Institute for Integrative Cancer Research. She holds a B.S. in veterinary science and an MBA in finance and accounting from the University of New Hampshire. - Janice Bourque自2019年7月起担任董事会成员。Bourque女士是Hercules Capital生命科学集团的常务董事，拥有超过25年的生命科学经验，专注于新兴成长阶段公司。在此之前，Bourque女士曾为Commons Capital提供咨询，担任Comerica Bank的高级副总裁和生命科学集团负责人，并担任马萨诸塞州生物技术委员会主席兼首席执行官。Bourque女士目前在Poxel，SA和The Village Bank的董事会任职。Bourque女士还担任麻省理工学院科赫综合癌症研究所（MIT Koch Institute for Integrative Cancer Research）的董事会成员。她持有the University of New Hampshire的兽医科学B.S.和财务和会计工商管理硕士学位。
- Janice Bourque has served as a member of Board since July 2019. Ms. Bourque is a Managing Director in Hercules Capital's life sciences group and has more than 25 years of life science experience and a focus on emerging growth stage companies. Previously, Ms. Bourque has consulted for Commons Capital, served as Senior Vice President and Group Head Life Sciences at Comerica Bank and was President and Chief Executive Officer of the Massachusetts Biotechnology Council. Ms. Bourque currently serves on the board of directors of Poxel, SA and the Village Bank. Ms. Bourque has also served on the board of directors of the MIT Koch Institute for Integrative Cancer Research. She holds a B.S. in veterinary science and an MBA in finance and accounting from the University of New Hampshire.
- Charles Swanton
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Felix J. Baker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Fabrice Andre
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alessandro Riva
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Stephen Sands
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Roger Danse
-
Roger Danse，目前担任Inovio Inc.和Ottimo Pharma的董事会成员。此前，他是临时首席肿瘤官和辉瑞肿瘤学首席开发官。在辉瑞收购该公司之前，丹西博士还曾在Seagen担任首席医疗官和研发总裁。在其职业生涯的早期，他曾在默沙东、吉利德科学和安进担任高级领导职务。丹西博士在包括Keytruda在内的众多重要癌症疗法的开发和批准过程中发挥了关键作用（pembrolizumab）、XGEVA/Prolia（denosumab）、Zydelig（idelalisib）、adcetris（brentuximab vedotin）、Padcev（enfortumab vedotin），Tivdak（tisotumab vedotin）和Tukysa（tucatinib）。他拥有南非约翰内斯堡威特沃特斯兰德大学的医学博士学位，在加入工业界之前，他是底特律Karmanos癌症研究所的血液学/肿瘤学副教授。
Roger Danse,currently serves on the Boards of Directors of Inovio Inc. and Ottimo Pharma. Previously, he was interim chief oncology officer and chief development officer of Pfizer Oncology. Dr. Dansey also served as chief medical officer and president of research and development at Seagen prior to Pfizer's acquisition of the company. Earlier in his career, he held senior leadership positions at Merck, Gilead Sciences and mgen. Dr. Dansey played a key role in the development and approvals of numerous important cancer therapies, including Keytruda (pembrolizumab), Xgeva/Prolia (denosumab), Zydelig (idelalisib), Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tivdak (tisotumab vedotin) and Tukysa (tucatinib). He holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa, and before joining industry, he was an associate professor of hematology/oncology at the Karmanos Cancer Institute in Detroit. - Roger Danse，目前担任Inovio Inc.和Ottimo Pharma的董事会成员。此前，他是临时首席肿瘤官和辉瑞肿瘤学首席开发官。在辉瑞收购该公司之前，丹西博士还曾在Seagen担任首席医疗官和研发总裁。在其职业生涯的早期，他曾在默沙东、吉利德科学和安进担任高级领导职务。丹西博士在包括Keytruda在内的众多重要癌症疗法的开发和批准过程中发挥了关键作用（pembrolizumab）、XGEVA/Prolia（denosumab）、Zydelig（idelalisib）、adcetris（brentuximab vedotin）、Padcev（enfortumab vedotin），Tivdak（tisotumab vedotin）和Tukysa（tucatinib）。他拥有南非约翰内斯堡威特沃特斯兰德大学的医学博士学位，在加入工业界之前，他是底特律Karmanos癌症研究所的血液学/肿瘤学副教授。
- Roger Danse,currently serves on the Boards of Directors of Inovio Inc. and Ottimo Pharma. Previously, he was interim chief oncology officer and chief development officer of Pfizer Oncology. Dr. Dansey also served as chief medical officer and president of research and development at Seagen prior to Pfizer's acquisition of the company. Earlier in his career, he held senior leadership positions at Merck, Gilead Sciences and mgen. Dr. Dansey played a key role in the development and approvals of numerous important cancer therapies, including Keytruda (pembrolizumab), Xgeva/Prolia (denosumab), Zydelig (idelalisib), Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tivdak (tisotumab vedotin) and Tukysa (tucatinib). He holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa, and before joining industry, he was an associate professor of hematology/oncology at the Karmanos Cancer Institute in Detroit.
- Hervé Hoppenot
-
Herv é Hoppenot是首席执行官的顾问，在担任公司董事长兼首席执行官11年后，在因塞特医疗的董事会任职。在他的领导下，因塞特医疗将临床候选药物的数量增加了两倍，在15个国家建立了国际影响力，并将收入从3.5亿美元增长到42亿美元。他还在Pierre Fabre Laboratories和N-Power Medicine的董事会任职。此前，Hoppenot先生曾担任诺华肿瘤公司总裁，最初是作为首席商务官加入的，负责监管业界最大的肿瘤管道。Hoppenot先生的职业生涯始于Rh ne Poulenc，后来被称为Aventis，在那里他担任过几个责任越来越大的高级职位，包括担任肿瘤学副总裁和美国肿瘤业务部门负责人。他拥有法国ESSEC商学院的学位。
Hervé Hoppenot,is an advisor to the CEO and serves on the Board of Directors of Incyte, after serving 11 years as the company's chairman and CEO. Under his leadership, Incyte tripled the number of clinical candidates, established an international presence in 15 countries and grew revenues from $350 million to $4.2 billion. He also serves on the Boards of Directors of Pierre Fabre Laboratories and N-Power Medicine. Previously, Mr. Hoppenot served as president of Novartis Oncology, originally joining as chief commercial officer, overseeing the industry's largest oncology pipeline. Mr. Hoppenot started his career at Rhne Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including as vice president of oncology and head of the U.S. oncology business unit. He holds a degree from ESSEC Business School in France. - Herv é Hoppenot是首席执行官的顾问，在担任公司董事长兼首席执行官11年后，在因塞特医疗的董事会任职。在他的领导下，因塞特医疗将临床候选药物的数量增加了两倍，在15个国家建立了国际影响力，并将收入从3.5亿美元增长到42亿美元。他还在Pierre Fabre Laboratories和N-Power Medicine的董事会任职。此前，Hoppenot先生曾担任诺华肿瘤公司总裁，最初是作为首席商务官加入的，负责监管业界最大的肿瘤管道。Hoppenot先生的职业生涯始于Rh ne Poulenc，后来被称为Aventis，在那里他担任过几个责任越来越大的高级职位，包括担任肿瘤学副总裁和美国肿瘤业务部门负责人。他拥有法国ESSEC商学院的学位。
- Hervé Hoppenot,is an advisor to the CEO and serves on the Board of Directors of Incyte, after serving 11 years as the company's chairman and CEO. Under his leadership, Incyte tripled the number of clinical candidates, established an international presence in 15 countries and grew revenues from $350 million to $4.2 billion. He also serves on the Boards of Directors of Pierre Fabre Laboratories and N-Power Medicine. Previously, Mr. Hoppenot served as president of Novartis Oncology, originally joining as chief commercial officer, overseeing the industry's largest oncology pipeline. Mr. Hoppenot started his career at Rhne Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including as vice president of oncology and head of the U.S. oncology business unit. He holds a degree from ESSEC Business School in France.
高管简历
中英对照 | 中文 | 英文- Kevin Lee
Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
Kevin Lee,has served as Chief Executive Officer and a member of Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020.- Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
- Kevin Lee,has served as Chief Executive Officer and a member of Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020.
- Michael Skynner
Michael Skynner自2018年1月起担任我们的首席运营官，在此之前，自2016年1月起担任我们的运营Vice President。在加入我们之前，Skynner博士于2013年9月至2016年1月在制药公司辉瑞公司工作，担任罕见疾病联盟负责人，领导欧洲的罕见疾病工作，并创立和运营辉瑞罕见疾病联盟。在加入辉瑞之前，Skynner博士从2008年5月到2013年9月在GlaxoSmithKline plc工作，专注于开发针对炎性激酶的治疗药物。任职GlaxoSmithKline公司之前，Skynner博士于2001年共同创立Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum公司之前，专门开发用于炎症和代谢性疾病的小分子和多肽疗法。Skynner博士在帝国理工学院（Imperial College）获得生物化学博士学位。
Michael Skynner has served as Chief Operating Officer since January 2018 and prior to this, served as Vice President of Operations since January 2016. Prior to joining, Dr. Skynner worked at Pfizer Inc., a pharmaceutical company, from September 2013 to January 2016 where he was Head of Rare Disease Alliances, led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium. Prior to Pfizer, from May 2008 to September 2013 Dr. Skynner worked at GlaxoSmithKline plc, where he focused on developing therapeutics targeting inflammatory kinases. Prior to GlaxoSmithKline, in 2001 Dr. Skynner co-founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005. Dr. Skynner obtained his Ph.D. in biochemistry from Imperial College.- Michael Skynner自2018年1月起担任我们的首席运营官，在此之前，自2016年1月起担任我们的运营Vice President。在加入我们之前，Skynner博士于2013年9月至2016年1月在制药公司辉瑞公司工作，担任罕见疾病联盟负责人，领导欧洲的罕见疾病工作，并创立和运营辉瑞罕见疾病联盟。在加入辉瑞之前，Skynner博士从2008年5月到2013年9月在GlaxoSmithKline plc工作，专注于开发针对炎性激酶的治疗药物。任职GlaxoSmithKline公司之前，Skynner博士于2001年共同创立Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum公司之前，专门开发用于炎症和代谢性疾病的小分子和多肽疗法。Skynner博士在帝国理工学院（Imperial College）获得生物化学博士学位。
- Michael Skynner has served as Chief Operating Officer since January 2018 and prior to this, served as Vice President of Operations since January 2016. Prior to joining, Dr. Skynner worked at Pfizer Inc., a pharmaceutical company, from September 2013 to January 2016 where he was Head of Rare Disease Alliances, led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium. Prior to Pfizer, from May 2008 to September 2013 Dr. Skynner worked at GlaxoSmithKline plc, where he focused on developing therapeutics targeting inflammatory kinases. Prior to GlaxoSmithKline, in 2001 Dr. Skynner co-founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005. Dr. Skynner obtained his Ph.D. in biochemistry from Imperial College.
- Travis Thompson
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Eric Westin
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Alethia Young
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Alistair Milnes
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Michael Charles Ferguson Hannay
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jim MacDonald Clink
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介